Processa Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
PCSA Processa Pharmaceuticals Inc
ZTS Zoetis Inc
HMPT Home Point Capital Inc
KWR Quaker Chemical Corp
TWO Two Harbors Investment Corp
BV Brightview Holdings Inc
PBPB Potbelly Corp
RLJ RLJ Lodging Trust
LHCG LHC Group Inc
KW Kennedy-Wilson Holdings Inc
Go

Health Care : Pharmaceuticals | Small Cap Growth
Company profile

Processa Pharmaceuticals, Inc., formerly Heatwurx, Inc., is a pharmaceutical company. The Company is focused on the development of drug products that are intended to improve the survival and/or quality of life for patients who have unmet medical need. The Company’s product portfolio includes 499. It is developing 499 for the treatment of Necrobiosis Lipoidica. It is also developing 499 for the treatment of effects related to head and neck cancer.

Closing Price
$7.14
Day's Change
-0.58 (-7.51%)
Bid
--
Ask
--
B/A Size
--
Day's High
7.90
Day's Low
6.62
Volume
(Heavy Day)
Volume:
107,483

10-day average volume:
54,781
107,483
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Copyright © 2021. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.